Citations

Citations to this article as recorded by  

• Adherence to the nutritional recommendations according to diabetes status in Korean adults: a cross-sectional study
  Jong Han Choi, Chen Lulu, Seon-Joo Park, Hae-Jeung Lee
  BMC Public Health.2024;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
  Hye Soon Kim
  Diabetes & Metabolism Journal.2024; 48(5): 882.     CrossRef

Citations

Citations to this article as recorded by  

• Changes in urinary renal injury markers in children with Mycoplasma pneumoniae pneumonia and a prediction model for related early renal injury
  Ju Zhang, He-kai Ma, Bao-wen Li, Ke-Ke Ma, Yu-Ling Zhang, Shu-jun Li
  Italian Journal of Pediatrics.2024;[Epub]     CrossRef
• Intermittent fasting plus early time-restricted eating versus calorie restriction and standard care in adults at risk of type 2 diabetes: a randomized controlled trial
  Xiao Tong Teong, Kai Liu, Andrew D. Vincent, Julien Bensalem, Bo Liu, Kathryn J. Hattersley, Lijun Zhao, Christine Feinle-Bisset, Timothy J. Sargeant, Gary A. Wittert, Amy T. Hutchison, Leonie K. Heilbronn
  Nature Medicine.2023; 29(4): 963.     CrossRef
• Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease
  Jaehyun Bae, Byung-Wan Lee
  Biomedicines.2023; 11(7): 1928.     CrossRef
• Abdominal adipose tissue and type 2 diabetic kidney disease: adipose radiology assessment, impact, and mechanisms
  Fei Lu, Jinlei Fan, Fangxuan Li, Lijing Liu, Zhiyu Chen, Ziyu Tian, Liping Zuo, Dexin Yu
  Abdominal Radiology.2023; 49(2): 560.     CrossRef
• β‐Amyrin ameliorates diabetic nephropathy in mice and regulates the miR‐181b‐5p/HMGB2 axis in high glucose‐stimulated HK‐2 cells
  Wenhua Xu, Hongwu Zhang, Qinfeng Zhang, Jialan Xu
  Environmental Toxicology.2022; 37(3): 637.     CrossRef
• High Glycated Hemoglobin Instead of High Body Mass Index Might Increase the Urine N-Acetyl-β-D-glucosaminidase Con-Centration in Children and Adolescents with Diabetes Mellitus
  Jin-Soon Suh, Kyoung Soon Cho, Seul Ki Kim, Shin-Hee Kim, Won Kyoung Cho, Min Ho Jung, Moon Bae Ahn
  Life.2022; 12(6): 879.     CrossRef

Citations

Citations to this article as recorded by  

• Thiazolidinediones: Recent Development in Analytical Methodologies
  Tarang Patel, Vatsal Patel
  Journal of Chromatographic Science.2024; 62(8): 789.     CrossRef
• Etiology of Drug-Induced Edema: A Review of Dihydropyridine, Thiazolidinedione, and Other Medications Causing Edema
  Evan S Sinnathamby, Bretton T Urban, Robert A Clark, Logan T Roberts, Audrey J De Witt, Danielle M Wenger, Aya Mouhaffel, Olga Willett, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye, Giustino Varrassi
  Cureus.2024;[Epub]     CrossRef
• Novel thiazolidin-4-one benzenesulfonamide hybrids as PPARγ agonists: Design, synthesis and in vivo anti-diabetic evaluation
  Islam H. Ali, Rasha M. Hassan, Ahmed M. El Kerdawy, Mahmoud T. Abo-Elfadl, Heba M.I. Abdallah, Francesca Sciandra, Iman A.Y. Ghannam
  European Journal of Medicinal Chemistry.2024; 269: 116279.     CrossRef
• The role of the methoxy group in approved drugs
  Debora Chiodi, Yoshihiro Ishihara
  European Journal of Medicinal Chemistry.2024; 273: 116364.     CrossRef
• Thiazolidinedione an auspicious scaffold as PPAR-γ agonist: its possible mechanism to Manoeuvre against insulin resistant diabetes mellitus
  Sourav Basak, Anjali Murmu, Balaji Wamanrao Matore, Partha Pratim Roy, Jagadish Singh
  European Journal of Medicinal Chemistry Reports.2024; 11: 100160.     CrossRef
• Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high‐performance thin layer chromatographic method
  Ashim Kumar Sen, Tantul Sarkar, Dhanya B. Sen, Rajesh A. Maheshwari, Aarti S. Zanwar, Rajesh L. Dumpala
  SEPARATION SCIENCE PLUS.2024;[Epub]     CrossRef
• A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties
  Antonio Laghezza, Carmen Cerchia, Massimo Genovese, Roberta Montanari, Davide Capelli, Judith Wackerlig, Stefan Simic, Emanuele Falbo, Lucia Pecora, Rosalba Leuci, Leonardo Brunetti, Luca Piemontese, Paolo Tortorella, Abanish Biswas, Ravi Pratap Singh, Su
  European Journal of Medicinal Chemistry.2024; 275: 116567.     CrossRef
• Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis
  Deep Dutta, Jyoti Kadian, Indira Maisnam, Ashok Kumar, Saptarshi Bhattacharya, Meha Sharma
  Indian Journal of Endocrinology and Metabolism.2023; 27(4): 286.     CrossRef
• Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
  Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
• Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis
  Shashank R. Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102703.     CrossRef
• Synthesis, Characterization, and Pharmacokinetic Studies of Thiazolidine-2,4-Dione Derivatives
  Bushra Ansari, Haroon Khan, Muhammad Saeed Jan, Khalaf F. Alsharif, Khalid J. Alzahrani, Umer Rashid, Abdul Saboor Pirzada, Vinod Kumar Tiwari
  Journal of Chemistry.2023; 2023: 1.     CrossRef
• Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
  Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(4): 102747.     CrossRef
• Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
  Heeyoung Kim, Choon Ok Kim, Hyeonsoo Park, Min Soo Park, Dasohm Kim, Taegon Hong, Yesong Shin, Byung Hak Jin
  Translational and Clinical Pharmacology.2023; 31(1): 59.     CrossRef
• Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
  Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
  Cardiovascular Diabetology.2023;[Epub]     CrossRef
• Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model
  Yun Kyung Lee, Tae Jung Oh, Ji In Lee, Bo Yoon Choi, Hyen Chung Cho, Hak Chul Jang, Sung Hee Choi
  European Journal of Pharmacology.2023; 957: 175946.     CrossRef
• Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
  Shotaro Kamata, Akihiro Honda, Isao Ishii
  Biomolecules.2023; 13(8): 1264.     CrossRef
• Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
  Hye-Young Seo, So-Hee Lee, Ji Yeon Park, Eugene Han, Sol Han, Jae Seok Hwang, Mi Kyung Kim, Byoung Kuk Jang, Kenji Fujiwara
  PLOS ONE.2023; 18(8): e0290532.     CrossRef
• Insulin sensitizers in 2023: lessons learned and new avenues for investigation
  Jerry R. Colca, Steven P. Tanis, Rolf F. Kletzien, Brian N. Finck
  Expert Opinion on Investigational Drugs.2023; 32(9): 803.     CrossRef
• Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach
  Priyamvada Amol Arte, Kanchanlata Tungare, Mustansir Bhori, Renitta Jobby, Jyotirmoi Aich
  Human Cell.2023; 37(1): 54.     CrossRef
• Lobeglitazone and Its Therapeutic Benefits: A Review
  Balamurugan M, Sarumathy S, Robinson R
  Cureus.2023;[Epub]     CrossRef
• Diabetes and diabesity in the view of proteomics, drug, and plant-derived remedies
  Mohammad Reza Haeri
  Journal of Research in Medical Sciences.2023;[Epub]     CrossRef
• A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
  Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
  Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
• Effect of the addition of thiazolidinedione to sodium-glucose cotransporter 2 inhibitor therapy on lipid levels in type 2 diabetes mellitus: a retrospective study using Korean National Health Insurance Service data
  Taegyun Park, Kyungdo Han, Dongwook Shin, Jongho Park
  Cardiovascular Prevention and Pharmacotherapy.2022; 4(3): 114.     CrossRef
• Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents
  Vassiliki‐Panagiota Tassopoulou, Ariadni Tzara, Angeliki P. Kourounakis
  ChemMedChem.2022;[Epub]     CrossRef
• A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
  Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Y
  Diabetes & Metabolism Journal.2022; 46(6): 855.     CrossRef
• Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
  Dabin Jeong, Wan-Kyu Ko, Seong-Jun Kim, Gong-Ho Han, Daye Lee, Seung-Hun Sheen, Seil Sohn
  Biomedicines.2021; 9(10): 1432.     CrossRef

Citations

Citations to this article as recorded by  

• SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
  Nasser Safaie, Shahab Masoumi, Shaban Alizadeh, Pourya Mirzajanzadeh, Hamid Reza Nejabati, Mobasher Hajiabbasi, Vahid Alivirdiloo, Neda Chobdari Basmenji, Aysan Derakhshi Radvar, Ziba Majidi, Yousef Faridvand
  Cell Biochemistry and Function.2024;[Epub]     CrossRef
• Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states
  Mehmet Kanbay, Sidar Copur, Mustafa Guldan, Lasin Ozbek, Alper Hatipoglu, Adrian Covic, Francesca Mallamaci, Carmine Zoccali
  Clinical Kidney Journal.2024;[Epub]     CrossRef
• Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
  Yafei Xie, Yujie Wei, Dan Li, Jie Pu, Hong Ding, Xiaowei Zhang
  Journal of Cardiovascular Pharmacology.2023; 81(1): 4.     CrossRef
• Current Treatment Options, Including Diet, Exercise, and Medications
  Mazen Noureddin, Manal F. Abdelmalek
  Clinics in Liver Disease.2023; 27(2): 397.     CrossRef
• SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
  Panagiotis Theofilis, Rigas G. Kalaitzidis
  Current Medicinal Chemistry.2023; 30(23): 2595.     CrossRef
• Treatment of obesity-related diabetes: significance of thermogenic adipose tissue and targetable receptors
  Ruping Pan, Jiadai Liu, Yong Chen
  Frontiers in Pharmacology.2023;[Epub]     CrossRef
• Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
  Ema Schönberger, Vjera Mihaljević, Kristina Steiner, Sandra Šarić, Tomislav Kurevija, Ljiljana Trtica Majnarić, Ines Bilić Ćurčić, Silvija Canecki-Varžić
  International Journal of Environmental Research and Public Health.2023; 20(17): 6671.     CrossRef
• SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model
  Manal Moustafa Mahmoud, Laila Ahmed Rashed, Somia Abdulatif Soliman, Safaa Mostafa Sayed, Omneya Kamel, Samaa Samir Kamar, Rania El Sayed Hussien
  Physiological Reports.2023;[Epub]     CrossRef
• Resting energy expenditure based on equation estimation can predict renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease
  Xiang Xiao, Shuming Ji, Junlin Zhang, Deying Kang, Fang Liu
  Renal Failure.2023;[Epub]     CrossRef
• Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy
  Zhicheng Gao, Jiaqi Bao, Yilan Hu, Junjie Tu, Lifang Ye, Lihong Wang
  Current Drug Targets.2023; 24(13): 1009.     CrossRef
• SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1
  Weijie Wang, Yilan Li, Yanxiu Zhang, Tao Ye, Kui Wang, Shuijie Li, Yao Zhang
  Cardiovascular Diabetology.2023;[Epub]     CrossRef
• Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling
  Ke Lin, Na Yang, Wu Luo, Jin-fu Qian, Wei-wei Zhu, Shi-ju Ye, Chen-xin Yuan, Di-yun Xu, Guang Liang, Wei-jian Huang, Pei-ren Shan
  Acta Pharmacologica Sinica.2022; 43(10): 2624.     CrossRef
• Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
  Panagiotis Theofilis, Marios Sagris, Evangelos Oikonomou, Alexios S. Antonopoulos, Gerasimos Siasos, Kostas Tsioufis, Dimitris Tousoulis
  Diabetes Research and Clinical Practice.2022; 188: 109927.     CrossRef
• Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
  Sandra Feijóo-Bandín, Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Oreste Gualillo, José Ramón González-Juanatey, Francisca Lago
  International Journal of Molecular Sciences.2022; 23(10): 5634.     CrossRef
• Potential molecular mechanism of action of sodium-glucose co-transporter 2 inhibitors in the prevention and management of diabetic retinopathy
  Lia Meuthia Zaini, Arief S Kartasasmita, Tjahjono D Gondhowiardjo, Maimun Syukri, Ronny Lesmana
  Expert Review of Ophthalmology.2022; 17(3): 199.     CrossRef
• New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
  Juexing Li, Lei Zhou, Hui Gong
  Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
• Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
  Milton Packer
  Circulation.2022; 146(18): 1383.     CrossRef
• Nutraceutical activation of Sirt1: a review
  James J DiNicolantonio, Mark F McCarty, James H O'Keefe
  Open Heart.2022; 9(2): e002171.     CrossRef
• Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
  Jing Xu, Munehiro Kitada, Yoshio Ogura, Haijie Liu, Daisuke Koya
  Cells.2021; 10(6): 1457.     CrossRef
• Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations
  Dimitrios A. Vrachatis, Konstantinos A. Papathanasiou, Konstantinos E. Iliodromitis, Sotiria G. Giotaki, Charalampos Kossyvakis, Konstantinos Raisakis, Andreas Kaoukis, Vaia Lambadiari, Dimitrios Avramides, Bernhard Reimers, Giulio G. Stefanini, Michael C
  Drugs.2021; 81(12): 1381.     CrossRef
• Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes
  Milton Packer
  JACC: Heart Failure.2021; 9(8): 535.     CrossRef
• Ketone bodies: from enemy to friend and guardian angel
  Hubert Kolb, Kerstin Kempf, Martin Röhling, Martina Lenzen-Schulte, Nanette C. Schloot, Stephan Martin
  BMC Medicine.2021;[Epub]     CrossRef

This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NAFLD have an increased risk of non-alcoholic steatohepatitis (NASH) and fibrosis and a higher risk of cardiovascular diseases and diabetic complications compared to those without NAFLD. With regards to the evaluation of patients with T2DM and NAFLD, ultrasonography-based stepwise approaches using noninvasive biomarker models such as fibrosis-4 or the NAFLD fibrosis score as well as imaging studies such as vibration-controlled transient elastography with controlled attenuation parameter or magnetic resonance imaging-proton density fat fraction are recommended. After the diagnosis of NAFLD, the stage of fibrosis needs to be assessed appropriately. For management, weight reduction achieved by lifestyle modification has proven beneficial and is recommended in combination with antidiabetic agent(s). Evidence that some antidiabetic agents improve NAFLD/NASH with fibrosis in patients with T2DM is emerging. However, there are currently no definite pharmacologic treatments for NAFLD in patients with T2DM. For specific cases, bariatric surgery may be an option if indicated.

Citations

Citations to this article as recorded by  

• A combined extract containing Schisandra chinensis (SCE) reduced hepatic triglyceride accumulation in rats fed a high-sucrose diet
  Haneul Lee, Eun Young Kang, Joowon Lee, Yejin Kim, Sumin Kang, Hayoon Kim, Hyun Kyung Kim, Gyoungok Gang, Sang-gil Lee, Cao Lei, Gwang-woong Go
  Food Science and Biotechnology.2024; 33(6): 1449.     CrossRef
• Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
  Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
  BMJ.2024; : e076388.     CrossRef
• Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
  Inha Jung, Dae-Jeong Koo, Won-Young Lee
  Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
• Association between urinary polycyclic aromatic hydrocarbons and risk of metabolic associated fatty liver disease
  Minzhen Wang, Shaoyan Tang, Lulu Zhang, Yamin Zhao, Yindi Peng, Shan zheng, Zanchao Liu
  International Archives of Occupational and Environmental Health.2024; 97(7): 695.     CrossRef
• A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
  Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
  Diabetes & Metabolism Journal.2024; 48(4): 740.     CrossRef
• Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
  Xi Lu, Qingxing Xie, Xiaohui Pan, Ruining Zhang, Xinyi Zhang, Ge Peng, Yuwei Zhang, Sumin Shen, Nanwei Tong
  Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
• Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Man’s Land?
  Liliana Gheorghe, Roxana Nemteanu, Andreea Clim, Gina Eosefina Botnariu, Irina Iuliana Costache, Alina Plesa
  Life.2023; 13(4): 857.     CrossRef
• Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
  Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
  Metabolism.2023; 145: 155612.     CrossRef
• Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: A nationwide population-based study
  Goh Eun Chung, Kyungdo Han, Kyu-Na Lee, Jung Ho Bae, Sun Young Yang, Su-Yeon Choi, Jeong Yoon Yim, Nam Ju Heo
  Diabetes & Metabolism.2023; 49(4): 101454.     CrossRef
• Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
  Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim
  Clinical and Molecular Hepatology.2023; 29(3): 693.     CrossRef
• Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review
  Qingxing Xie, Xiaohui Pan, Xinyue Zhang, Jinfang Ma, Ge Peng, Nanwei Tong
  Chinese Medical Journal.2023; 136(16): 2014.     CrossRef
• Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus
  E. V. Uzhakova, Z. E. Zshanko, E. N. Smirnova
  Experimental and Clinical Gastroenterology.2023; (6): 121.     CrossRef
• Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model
  Yun Kyung Lee, Tae Jung Oh, Ji In Lee, Bo Yoon Choi, Hyen Chung Cho, Hak Chul Jang, Sung Hee Choi
  European Journal of Pharmacology.2023; 957: 175946.     CrossRef
• Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
  Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi
  Cell Death & Disease.2023;[Epub]     CrossRef
• 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
  Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
  Diabetes & Metabolism Journal.2023; 47(5): 575.     CrossRef
• Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
  Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
  Scientific Reports.2023;[Epub]     CrossRef
• Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non‐alcoholic fatty liver disease and metabolic dysfunction
  Aurelia Radulescu, Adam J. Dugan, Mary Killian, Suzanna L. Attia, Marialena Mouzaki, George J. Fuchs, Rohit Kohli, Henrietta Bada, Philip A. Kern, Samir Softic
  Pediatric Obesity.2022;[Epub]     CrossRef
• Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
  Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Diabetes & Metabolism Journal.2022; 46(1): 104.     CrossRef
• Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
  Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
  Endocrinology and Metabolism.2022; 37(1): 74.     CrossRef
• State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
  Yongin Cho, Yong-ho Lee
  Endocrinology and Metabolism.2022; 37(1): 38.     CrossRef
• Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
  Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jin-Young Choi, Yong-ho Lee
  BMC Medicine.2022;[Epub]     CrossRef
• Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
  Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
  Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
• Anti-Obesity and Anti-Hyperglycemic Effects of Meretrix lusoria Protamex Hydrolysate in ob/ob Mice
  Min Ju Kim, Ramakrishna Chilakala, Hee Geun Jo, Seung-Jae Lee, Dong-Sung Lee, Sun Hee Cheong
  International Journal of Molecular Sciences.2022; 23(7): 4015.     CrossRef
• The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
  Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Cumulative Exposure to High γ-Glutamyl Transferase Level and Risk of Diabetes: A Nationwide Population-Based Study
  Ji-Yeon Park, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
  Endocrinology and Metabolism.2022; 37(2): 272.     CrossRef
• SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
  Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael A. Nauck, Soo Lim
  Trends in Endocrinology & Metabolism.2022; 33(6): 424.     CrossRef
• Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
  Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
  International Journal of Molecular Sciences.2022; 23(9): 5035.     CrossRef
• Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
  Sihan Peng, Lu Liu, Ziyan Xie, Xiyu Zhang, Chunguang Xie, Sha Ye, Xiangeng Zhang, Xiaoli Liang, Hongyan Wang, Ya Liu
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
  Eugene Han, Mi Kyung Kim, Seung-Soon Im, Byoung Kuk Jang, Hye Soon Kim
  Journal of Diabetes and its Complications.2022; 36(8): 108253.     CrossRef
• Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
  Eun-Jung Rhee
  Endocrinology and Metabolism.2022; 37(3): 415.     CrossRef
• Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
  Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
  Biomedicines.2022; 10(7): 1669.     CrossRef
• Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
  Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
  The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022.     CrossRef
• Nonalcoholic fatty liver disease is associated with early left ventricular diastolic dysfunction in patients with type 2 diabeteS
  Walaa Sheba, Eman Morsy, Salah Altahan, Mona Ayaad, Sameh A. Lashen
  Alexandria Journal of Medicine.2022; 58(1): 117.     CrossRef
• The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study
  Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
  Diabetes Research and Clinical Practice.2022; 194: 110191.     CrossRef
• Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
  Ji Hye Huh
  Diabetes & Metabolism Journal.2022; 46(6): 953.     CrossRef
• The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
  Goh Eun Chung, Su-Min Jeong, Eun Ju Cho, Ji Won Yoon, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
  Jaehyun Bae, Young Jun Won, Byung-Wan Lee
  Life.2021; 11(3): 224.     CrossRef
• Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
  Sook Jung Lee, Byung-Wan Lee
  The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
• Non-alcoholic fatty liver disease
  Elizabeth E Powell, Vincent Wai-Sun Wong, Mary Rinella
  The Lancet.2021; 397(10290): 2212.     CrossRef
• Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
  In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
  Scientific Reports.2021;[Epub]     CrossRef
• Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
  A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
  Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
• Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
  Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
  Journal of the Endocrine Society.2021;[Epub]     CrossRef
• Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study
  Tracy Bonsu Osei, Anne-Marieke van Dijk, Sjoerd Dingerink, Felix Patience Chilunga, Erik Beune, Karlijn Anna Catharina Meeks, Silver Bahendeka, Matthias Bernd Schulze, Charles Agyemang, Mary Nicolaou, Adriaan Georgius Holleboom, Ina Danquah
  Nutrients.2021; 13(11): 3679.     CrossRef
• Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
  Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes
  Kyuho Kim, Tae Jung Oh, Hyen Chung Cho, Yun Kyung Lee, Chang Ho Ahn, Bo Kyung Koo, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang
  Scientific Reports.2021;[Epub]     CrossRef
• Evaluation of Grapefruit Juice in terms of Interleukin 18 Gene Expression in Rats with Fatty Liver and Healthy Rats
  Simin Bahmanpoor, Noosha Zia-Jahromi
  journal of ilam university of medical sciences.2021; 29(4): 74.     CrossRef

Citations

Citations to this article as recorded by  

• Association of statins with nonalcoholic fatty liver disease in patients with diabetes
  Raj Shah, Alexander Kong, Silvio De Melo, Moheb Boktor, Richard Henriquez, Amar Mandalia, Hrishikesh Samant, Carlos A. Alvarez, Ishak A. Mansi
  Journal of Investigative Medicine.2024; 72(6): 497.     CrossRef
• Comparing the Risk of Poor Outcomes Among Hepatitis C–Infected, Cured, and Never-Infected Controls
  Varun Saxena, Weilu Wu, Sreepriya Balasubramanian, Nizar Mukhtar, Suk I. Seo, Joanna B. Ready, Brock A. MacDonald, Julie A. Schmittdiel
  Gastro Hep Advances.2024; 3(6): 871.     CrossRef

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

Citations

Citations to this article as recorded by  

• Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
  Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
  BMJ.2024; : e076388.     CrossRef
• The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
  Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi
  Annals of Military and Health Sciences Research.2024;[Epub]     CrossRef
• Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
  强江 郭
  Advances in Clinical Medicine.2024; 14(03): 561.     CrossRef
• Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
  Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta
  Diabetes Research and Clinical Practice.2024; 211: 111650.     CrossRef
• Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
  Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi
  Expert Opinion on Pharmacotherapy.2024; 25(7): 925.     CrossRef
• Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
  Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi
  Archives of Physiology and Biochemistry.2023; 129(1): 76.     CrossRef
• Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
• Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease
  I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky, I. A. Antipov
  South Russian Journal of Therapeutic Practice.2023; 4(1): 68.     CrossRef
• An Ethyl Acetate Extract of Eryngium carlinae Inflorescences Attenuates Oxidative Stress and Inflammation in the Liver of Streptozotocin-Induced Diabetic Rats
  Cristian M. Trejo-Hurtado, Cinthia I. Landa-Moreno, Jenaro Lemus-de la Cruz, Donovan J. Peña-Montes, Rocío Montoya-Pérez, Rafael Salgado-Garciglia, Salvador Manzo-Avalos, Christian Cortés-Rojo, Juan Luis Monribot-Villanueva, José Antonio Guerrero-Analco,
  Antioxidants.2023; 12(6): 1235.     CrossRef
• Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
  Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich
  Profilakticheskaya meditsina.2023; 26(12): 95.     CrossRef
• Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
  Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
  Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
• Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
  Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
  Obesity.2022; 30(6): 1279.     CrossRef
• Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
  Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
  Journal of General Internal Medicine.2022; 37(16): 4153.     CrossRef
• Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
  Kyung-Soo Kim
  The Journal of Korean Diabetes.2022; 23(2): 83.     CrossRef
• Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
  Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Intestinal microbiota in the treatment of metabolically associated fatty liver disease
  Ji-Shuai Wang, Jin-Chun Liu
  World Journal of Clinical Cases.2022; 10(31): 11240.     CrossRef
• Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
  I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko
  Systemic Hypertension.2022; 19(1): 31.     CrossRef
• Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
  Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
  Nutrients.2022; 14(23): 4994.     CrossRef
• Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
  Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch
  Preventive Nutrition and Food Science.2022; 27(4): 384.     CrossRef
• NAFLDin type 2 diabetes mellitus: Still many challenging questions
  Simona Cernea, Itamar Raz
  Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
• Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
  Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
  Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
• Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes Therapy.2021; 12(1): 171.     CrossRef
• Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
  Sook Jung Lee, Byung-Wan Lee
  The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
• Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
  A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
  Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
• NAFLD and its link with diabetes: Why we should be worried
  Louise Cremonesini, Emma Harkin
  Independent Nurse.2021; 2021(8): 20.     CrossRef
• Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
  Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
• Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
  Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
  Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
  The Lancet Gastroenterology & Hepatology.2020; 5(9): 829.     CrossRef
• Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
  Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
  Medicine.2020; 99(33): e21038.     CrossRef
• Metabolic liver disease in diabetes – From mechanisms to clinical trials
  Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
  Metabolism.2020; 111: 154299.     CrossRef
• Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
  Siôn A. Parry, Leanne Hodson
  Advances in Therapy.2020; 37(4): 1381.     CrossRef
• Diabetes and Metabolism Journal in 2020: Good to Great
  In-Kyung Jeong
  Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
• Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
  Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
  Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
• Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
  Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
  Pharmacological Research.2020; 159: 104984.     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
• Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
  Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao
  Journal of Diabetes Investigation.2020; 11(5): 1238.     CrossRef
• Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
  Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
  Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef

Citations

Citations to this article as recorded by  

• Anti-hepatopathy and anti-nephropathy activities of Taraxacum officinale in a rat model of Streptozotocin diabetes-induced hepatorenal toxicity and dyslipidemia via attenuation of oxidative stress, inflammation, apoptosis, electrolyte imbalances, and mito
  Sunday Aderemi Adelakun, Aniah Julius Akomaye, Olusegun Dare Omotoso, Olukayode Abimbola Arowosegbe
  Aspects of Molecular Medicine.2024; 3: 100034.     CrossRef
• Epidemiology of heart failure in diabetes: a disease in disguise
  Anna G. Hoek, Elisa Dal Canto, Eva Wenker, Navin Bindraban, M. Louis Handoko, Petra J. M. Elders, Joline W. J. Beulens
  Diabetologia.2024; 67(4): 574.     CrossRef
• NASH triggers cardiometabolic HFpEF in aging mice
  Dániel Kucsera, Mihály Ruppert, Nabil V. Sayour, Viktória E. Tóth, Tamás Kovács, Zsombor I. Hegedűs, Zsófia Onódi, Alexandra Fábián, Attila Kovács, Tamás Radovits, Béla Merkely, Pál Pacher, Péter Ferdinandy, Zoltán V. Varga
  GeroScience.2024; 46(5): 4517.     CrossRef
• Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A2AR improves hepatic and cardiac dysfunction of NASH mice
  Chia-Chang Huang, Hsiao-Yun Yeh, Roger Lin, Tsai-Ling Liao, Hsiao-Chin Shen, Ying-Ying Yang, Han-Chieh Lin
  American Journal of Physiology-Gastrointestinal and Liver Physiology.2024; 326(4): G385.     CrossRef
• Is non-alcoholic fatty liver disease a sign of left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus? A systematic review and meta-analysis
  Sicheng Wang, Xiangyuan Zhang, Qiqi Zhang, Boxun Zhang, Linhua Zhao
  BMJ Open Diabetes Research & Care.2023; 11(1): e003198.     CrossRef
• The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study
  Seung Eun Lee, Juhwan Yoo, Bong-Seong Kim, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
  Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
• Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease
  Jose Arriola-Montenegro, Renato Beas, Renato Cerna-Viacava, Andres Chaponan-Lavalle, Karla Hernandez Randich, Diego Chambergo-Michilot, Herson Flores Sanga, Pornthira Mutirangura
  World Journal of Cardiology.2023; 15(7): 328.     CrossRef
• Non-alcoholic Fatty Liver Disease and Its Association With Left Ventricular Diastolic Dysfunction: A Systematic Review
  Namra V Gohil, Nida Tanveer, Vijaya Krishna Makkena, Arturo P Jaramillo, Babatope L Awosusi, Javaria Ayyub, Karan Nareshbhai Dabhi, Tuheen Sankar Nath
  Cureus.2023;[Epub]     CrossRef
• Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status
  Wangyan Jiang, Zhelong Liu, Shaohua Liu, Tingting Du
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis
  Athina Goliopoulou, Panagiotis Theofilis, Evangelos Oikonomou, Artemis Anastasiou, Panteleimon Pantelidis, Maria Ioanna Gounaridi, Georgios E. Zakynthinos, Ourania Katsarou, Eva Kassi, Vaia Lambadiari, Dimitris Tousoulis, Manolis Vavuranakis, Gerasimos Si
  International Journal of Molecular Sciences.2023; 24(18): 14292.     CrossRef
• Non-alcoholic fatty liver disease and risk of cardiovascular diseases: clinical association, pathophysiological mechanisms, and management
  Rong Yang, Jian-Gao Fan
  Cardiology Plus.2023; 8(4): 217.     CrossRef
• Association of cardiovascular factors in diabetic patients with non-alcoholic fatty liver disease
  Evangelos Cholongitas, Dimitrios Tsilingiris, Panagiota Diamantopoulou, Elpida Mastrogianni, Anastasios Tentolouris, Dimitrios Karagiannakis, Ioannis Moyssakis, George V. Papatheodoridis, Nikolaos Tentolouris
  Hormones.2022; 21(1): 133.     CrossRef
• Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis
  Jie Ning Yong, Cheng Han Ng, Chloe Wen-Min Lee, Yu Yi Chan, Ansel Shao Pin Tang, Margaret Teng, Darren Jun Hao Tan, Wen Hui Lim, Jingxuan Quek, Jieling Xiao, Yip Han Chin, Roger Foo, Mark Chan, Weiqin Lin, Mazen Noureddin, Mohammad Shadab Siddiqui, Mark D
  Hepatology International.2022; 16(2): 269.     CrossRef
• Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
  Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
  Obesity.2022; 30(6): 1279.     CrossRef
• Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology
  Dandan Peng, Zhenqiu Yu, Mingwei Wang, Junping Shi, Lei Sun, Yuanyuan Zhang, Wenbin Zhao, Chen Chen, Jiake Tang, Chunyi Wang, Jie Ni, Wen Wen, Jingjie Jiang
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
  Bing Chen, W.H. Wilson Tang, Mario Rodriguez, Kathleen E. Corey, Arun J. Sanyal, Patrick S. Kamath, Biykem Bozkurt, Hafeez Ul Hassan Virk, Gregg S. Pressman, Jeffrey V. Lazarus, Hashem B. El-Serag, Chayakrit Krittanawong
  Seminars in Liver Disease.2022; 42(04): 465.     CrossRef
• Nonalcoholic fatty liver disease is associated with early left ventricular diastolic dysfunction in patients with type 2 diabeteS
  Walaa Sheba, Eman Morsy, Salah Altahan, Mona Ayaad, Sameh A. Lashen
  Alexandria Journal of Medicine.2022; 58(1): 117.     CrossRef
• Cardiac abnormalities in patients with nonalcoholic fatty liver disease
  Yu Dong, Guangsen Li
  Herz.2021; 46(2): 158.     CrossRef
• Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters
  François Briand, Julie Maupoint, Emmanuel Brousseau, Natalia Breyner, Mélanie Bouchet, Clément Costard, Thierry Leste-Lasserre, Mathieu Petitjean, Li Chen, Audrey Chabrat, Virgile Richard, Rémy Burcelin, Caroline Dubroca, Thierry Sulpice
  Metabolism.2021; 117: 154707.     CrossRef
• Association of the Non‐Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: A cross‐sectional study in China
  Nengguang Fan, Xiaoying Ding, Qin Zhen, Liping Gu, Aifang Zhang, Tingting Shen, Yufan Wang, Yongde Peng
  Journal of Diabetes Investigation.2021; 12(6): 1035.     CrossRef
• Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes
  Minyoung Lee, Kwang Joon Kim, Tae‐Ha Chung, Jaehyun Bae, Yong‐ho Lee, Byung‐Wan Lee, Bong‐Soo Cha, Mijin Yun, Eun Seok Kang
  Diabetes, Obesity and Metabolism.2021; 23(4): 1041.     CrossRef
• Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
  Mohammad Said Ramadan, Vincenzo Russo, Gerardo Nigro, Emanuele Durante-Mangoni, Rosa Zampino
  Journal of Clinical Medicine.2021; 10(8): 1569.     CrossRef
• Correlation Between 25-Hydroxyvitamin D Level and Cardiac Diastolic Dysfunction in Chinese Adults with Early-Onset Type 2 Diabetes Mellitus: A Cross-Sectional Study
  Lei Xiu, Xiao-ai Yao, Tao Jiang
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 1823.     CrossRef
• Bi-directional and temporal relationship between elevated alanine aminotransferase and hypertension in a longitudinal study of Chinese adults
  Guoxin Huang, Hui Zhou, Chao Shen, Yihui Sheng, Ruyu Xue, Chen Dong, Shaoyan Zhang
  Clinical and Experimental Hypertension.2021; 43(8): 750.     CrossRef
• Response: Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus (Diabetes Metab J 2020;44:267–76)
  Hokyou Lee, Gyuri Kim, Yong-ho Lee
  Diabetes & Metabolism Journal.2020; 44(3): 486.     CrossRef
• Letter: Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus (Diabetes Metab J2020;44:267–76)
  Sung Hoon Yu
  Diabetes & Metabolism Journal.2020; 44(3): 482.     CrossRef

Citations

Citations to this article as recorded by  

• Predictors of efficacy of Sodium‐GLucose Transporter‐2 inhibitors and Glucagon‐Like Peptide 1 receptor agonists: A retrospective cohort study
  Daniele Scoccimarro, Giacomo Cipani, Ilaria Dicembrini, Edoardo Mannucci
  Diabetes/Metabolism Research and Reviews.2024;[Epub]     CrossRef
• Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study
  M. L. Morieri, I. Raz, A. Consoli, M. Rigato, A. Lapolla, F. Broglio, E. Bonora, A. Avogaro, G. P. Fadini, Federica Ginestra, Gloria Formoso, Agostino Consoli, Francesco Andreozzi, Giorgio Sesti, Salvatore Turco, Luigi Lucibelli, Adriano Gatti, Raffaella
  Journal of Endocrinological Investigation.2023; 46(7): 1429.     CrossRef
• Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review
  Katherine G. Young, Eram Haider McInnes, Robert J. Massey, Anna R. Kahkoska, Scott J. Pilla, Sridharan Raghavan, Maggie A. Stanislawski, Deirdre K. Tobias, Andrew P. McGovern, Adem Y. Dawed, Angus G. Jones, Ewan R. Pearson, John M. Dennis, Deirdre K. Tobi
  Communications Medicine.2023;[Epub]     CrossRef
• Predictors of HbA1c treatment response to add-on medication following metformin monotherapy: a population-based cohort study
  Wei Ying Tan, Wynne Hsu, Mong Li Lee, Ngiap Chuan Tan
  Scientific Reports.2023;[Epub]     CrossRef
• Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
  Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
  Diabetes & Metabolism Journal.2023; 47(6): 808.     CrossRef
• Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
  Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon
  Diabetes & Metabolism Journal.2021; 45(3): 339.     CrossRef
• Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
  Kana N. Miyata, Chao-Sheng Lo, Shuiling Zhao, Min-Chun Liao, Yuchao Pang, Shiao-Ying Chang, Junzheng Peng, Matthias Kretzler, Janos G. Filep, Julie R. Ingelfinger, Shao-Ling Zhang, John S.D. Chan
  Clinical Science.2021; 135(7): 943.     CrossRef
• Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
  Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
  Diabetes & Metabolism Journal.2020; 44(4): 489.     CrossRef
• Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
  Francesco Giorgino, Irene Caruso, Julia Moellmann, Michael Lehrke
  Metabolism.2020; 104: 154045.     CrossRef
• Clinical Predictors of the Hypoglycemic Effect of Sodium–Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study
  Toshinori Hirai, Yuya Kawagoe, Motoki Kei, Ryuichi Ogawa, Toshimasa Itoh
  Biological and Pharmaceutical Bulletin.2020; 43(5): 782.     CrossRef
• Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
  Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
  Kidney Research and Clinical Practice.2020; 39(3): 269.     CrossRef
• Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
  Ildiko Lingvay, Matthew S Capehorn, Andrei-Mircea Catarig, Pierre Johansen, Jack Lawson, Anna Sandberg, Robert Shaw, Abby Paine
  The Journal of Clinical Endocrinology & Metabolism.2020; 105(12): e4593.     CrossRef
• Letter: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
  Kyung-Soo Kim
  Diabetes & Metabolism Journal.2019; 43(3): 377.     CrossRef
• Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
  Ji-Yeon Lee, Eun Seok Kang
  Diabetes & Metabolism Journal.2019; 43(3): 379.     CrossRef
• An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
  Ji A Seo
  Diabetes & Metabolism Journal.2019; 43(5): 578.     CrossRef

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general population (around 25%), 50% to 70% of people with diabetes have NAFLD, and NAFLD severity (including fibrosis) tends to be worsened by the presence of diabetes. NAFLD is considered an emerging risk factor for type 2 diabetes mellitus and a contributor to the development of chronic diabetes-related complications. This reciprocal relationship demonstrates the importance of confirming suspected NAFLD in patients with diabetes. Due to the invasive nature of liver biopsy to assess NAFLD status, various alternative non-invasive modalities have been developed and validated. Here, we summarized the epidemiology of NAFLD in patients with diabetes and reviewed currently available imaging modalities and biomarker-based prediction models for their ability to detect liver steatosis and/or fibrosis.

Citations

Citations to this article as recorded by  

• Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
  Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng
  Critical Reviews in Food Science and Nutrition.2024; 64(17): 5768.     CrossRef
• Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
  Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
  Metabolism.2024; 152: 155789.     CrossRef
• Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes
  Sejeong Lee, Jaehyun Bae, Seung Up Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• ZJU Index as a Predictive Tool for Diabetes Incidence: Insights from a Population-Based Cohort Study
  Chenjiao Wu, Yi Hao Loh, Hangkai Huang, Chengfu Xu
  Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 715.     CrossRef
• Genetically engineered long-acting Esculentin-2CHa(1−30) fusion protein with potential applicability for the treatment of NAFLD
  Jaewoong Lee, Reeju Amatya, Kyung Eun Kim, Young-Hoon Park, Eunmi Hong, Krismala Djayanti, Kyoung Ah Min, Gu Seob Roh, Meong Cheol Shin
  Journal of Controlled Release.2024; 372: 699.     CrossRef
• Sigmoidal relationship between liver fat content and nonalcoholic fatty liver disease in Chinese adults
  Pingping Yu, Huachao Yang, Hu Li, Ying Mei, Yuanyuan Wu, Hongfeng Cheng, Huiru Su, Yueling Deng, Tao Jiang, Zhongxiang He, Peng Hu
  Postgraduate Medical Journal.2024; 100(1186): 562.     CrossRef
• Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
  Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Timothy Rolph, Andrew Cheng, Kitty Yale
  Clinical Gastroenterology and Hepatology.2024;[Epub]     CrossRef
• Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography
  Gyuri Kim, Tae Yang Yu, Jae Hwan Jee, Ji Cheol Bae, Mira Kang, Jae Hyeon Kim
  Diabetes & Metabolism.2024; 50(3): 101534.     CrossRef
• Anthropometry, laboratory, and PNPLA3 polymorphisms in a novel model for early identification and evaluation of nonalcoholic fatty liver disease
  Amal A. Mohamed, Rania Al Dweik, Reem A. Abdelghafour, Ahmed Ramadan, Abbas M. Abbas, Hussein H. Samir, Nashwa M. Muharram, Randa Ibrahim Ahmed Elshiha, Naglaa El-Salawy, Doaa Ghaith, Marwa K. Darwish, Soha M. Abd El Salam, Eman A. Sultan, Amina S. Solima
  Informatics in Medicine Unlocked.2024; 48: 101513.     CrossRef
• Relationship between fibrosis-4 score and microvascular complications in patients with type 2 diabetes mellitus
  Beril Turan Erdogan, Abbas Ali Tam, Husniye Baser, Fatma Neslihan Cuhaci Seyrek, Sefika Burcak Polat, Reyhan Ersoy, Oya Topaloglu, Bekir Cakir
  Arab Journal of Gastroenterology.2024; 25(3): 269.     CrossRef
• The relationship between muscle mass and fat content in body composition and non-alcoholic fatty liver disease in the Chinese general population: a cross-sectional study
  Guoqiong Xu, Yuanyuan Wu, Jie Chen, Dan Xiang, Dongji Li
  Frontiers in Medicine.2024;[Epub]     CrossRef
• Noninvasive Liver Fibrosis Indices as Indicators of Microvascular and Macrovascular Complications in Type 2 Diabetes
  Hande Erman, Banu Boyuk, Seyma Arslan, Seydahmet Akin, Özcan Keskin
  Metabolic Syndrome and Related Disorders.2024; 22(8): 619.     CrossRef
• Grading of Fatty Liver Based on Computed Tomography Hounsfield Unit Values versus Ultrasonography Grading
  Sultan Abdulwadoud Alshoabi, Reyan Mohammed Alharbi, Rufaydah Bader Algohani, Shahad Abdullah Alahmadi, Maryam Ahmed, Samah F. Faqeeh, Dalal Alahmadi, Abdulaziz A. Qurashi, Fahad H. Alhazmi, Rakan Mohammed Alrehaili, Abdulrahman Khalil Almughathawi
  Gastroenterology Insights.2024; 15(3): 588.     CrossRef
• Building in vitro models for mechanistic understanding of liver regeneration in chronic liver diseases
  Khushi Karnawat, Rithika Parthasarathy, Mesevilhou Sakhrie, Harikeshav Karthik, Konatala Vibhuvan Krishna, Gowri Manohari Balachander
  Journal of Materials Chemistry B.2024; 12(32): 7669.     CrossRef
• Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies
  Patrycja Jakubek, Barbara Pakula, Martin Rossmeisl, Paolo Pinton, Alessandro Rimessi, Mariusz Roman Wieckowski
  Internal and Emergency Medicine.2024; 19(5): 1473.     CrossRef
• Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems
  Sonal Kumar, Arpan Mohanty, Parvez Mantry, Robert E. Schwartz, Madeleine Haff, George Therapondos, Mazen Noureddin, Douglas Dieterich, Nigel Girgrah, Kristi Cohn, Mohanish Savanth, Michael Fuchs
  BMC Primary Care.2024;[Epub]     CrossRef
• Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
  In‐Kyung Jeong, Kyung Mook Choi, Kyung Ah Han, Kyoung‐Ah Kim, In Joo Kim, Seung Jin Han, Won Young Lee, Soon Jib Yoo
  Diabetes, Obesity and Metabolism.2024; 26(11): 5065.     CrossRef
• Plasma Adiponectin and Its Correlation with Carotid Intima-Media Thickness in Obesity and in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
  Maha Hussein, Aasem Saif, Mona Amin, Osama Khalafallah, Ahmed Hussien, Samar Aboulsoud, Shrook Mousa, S. Razzaque Mohammed
  Journal of Nutrition and Metabolism.2023; 2023: 1.     CrossRef
• Exposure to Bisphenol A, S, and F and its Association with Obesity and Diabetes Mellitus in General Adults of Korea: Korean National Environmental Health Survey (KoNEHS) 2015–2017
  Min Kyong Moon, Min Joo Kim, Inae Lee, Sunmi Kim, Sohyeon Choi, Jeongim Park, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Hyunwoong Park, Gi Jeong Cheon, Young Joo Park, Kyungho Choi
  Exposure and Health.2023; 15(1): 53.     CrossRef
• Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice
  Rosanna Villani, Grazia Pia Magnati, Giulia Tuccari, Moris Sangineto, Antonino Davide Romano, Tommaso Cassano, Gaetano Serviddio
  Ultrasound.2023; 31(3): 177.     CrossRef
• Association of cardiovascular health metrics with annual incidence of prediabetes or diabetes: Analysis of a nationwide real‐world database
  Akira Okada, Hidehiro Kaneko, Satoshi Matsuoka, Hidetaka Itoh, Yuta Suzuki, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Koichi Node, Toshimasa Yamauchi, Hideo Yasunaga, Issei Komuro
  Journal of Diabetes Investigation.2023; 14(3): 452.     CrossRef
• Effects of Environmental Cadmium Exposure on the Liver in Korean Adults: Cross-Sectional and Longitudinal Studies
  Mi-Na Seo, Sang-Yong Eom, Ji-Ae Lim, Jung-Eum Lee, Byung-Sun Choi, Ho-Jang Kwon, Young-Seoub Hong, Heon Kim, Jung-Duck Park
  Archives of Environmental Contamination and Toxicology.2023; 84(2): 237.     CrossRef
• Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
  Anika Bilal, Richard E. Pratley
  Endocrinology and Metabolism Clinics of North America.2023; 52(2): 355.     CrossRef
• CD24 Gene Expression as a Risk Factor for Non-Alcoholic Fatty Liver Disease
  Mona A. Amin, Halla M. Ragab, Nabila Abd El Maksoud, Wafaa Abd Elaziz
  Diagnostics.2023; 13(5): 984.     CrossRef
• Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
• Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus
  Yongin Cho, Hye-Sun Park, Byung Wook Huh, Yong-ho Lee, Seong Ha Seo, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, So Hun Kim
  Diabetes & Metabolism Journal.2023; 47(2): 232.     CrossRef
• Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
  Yuetian Yu, Yuefeng Yu, Yuying Wang, Yi Chen, Ningjian Wang, Bin Wang, Yingli Lu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• β-sitosterol attenuates high- fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway
  Omayma AR Abo-Zaid, Fatma SM Moawed, Effet Soliman Ismail, Mostafa A. Farrag
  BMC Pharmacology and Toxicology.2023;[Epub]     CrossRef
• Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
  Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park
  Diabetes & Metabolism Journal.2023; 47(3): 347.     CrossRef
• Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
  Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
  Metabolism.2023; 145: 155612.     CrossRef
• Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value
  Yu-Qi Li, Lei Xin, Yu-Chi Zhao, Shang-Qi Li, Ya-Nuo Li
  World Journal of Hepatology.2023; 15(6): 786.     CrossRef
• Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
  So Hee Park, Jiyun Park, So Yoon Kwon, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Janghyun Koh, Jae Hwan Jee, Jae Hyeon Kim, Mira Kang, Sang-Man Jin
  Scientific Reports.2023;[Epub]     CrossRef
• Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease
  Jaehyun Bae, Byung-Wan Lee
  Biomedicines.2023; 11(7): 1928.     CrossRef
• An Evidence-Based Review of Diabetes Care: History, Types, Relationship to Cancer and Heart Disease, Co-Morbid Factors, and Preventive Measures
  Umesh Chandra Gupta, Subhas Chandra Gupta, Shayle Sugandh Gupta
  Current Nutrition & Food Science.2023; 19(4): 399.     CrossRef
• Associations of serum aminotransferase and the risk of all-cause and cause-specific mortality in Chinese type 2 diabetes: a community-based cohort study
  Jian Su, Haoyu Guan, Xikang Fan, Hao Yu, Yu Qin, Jie Yang, Zheng Zhu, Chong Shen, Enchun Pan, Yan Lu, Jin-Yi Zhou, Ming Wu
  BMJ Open.2023; 13(7): e068160.     CrossRef
• Retinoic acid signaling in fatty liver disease
  Fathima N. Cassim Bawa, Yanqiao Zhang
  Liver Research.2023; 7(3): 189.     CrossRef
• Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
  Reeju Amatya, Donghee Lee, Kyoung Ah Min, Meong Cheol Shin
  Pharmaceutics.2023; 15(7): 1963.     CrossRef
• Prevalence of Non-Alcoholic Fatty Liver Disease and Its Risk Factors in Korean Population
  Sang Gyeong Lee, Songchan Oh, Moon Seong Kim, Jooyeon Kim, Eunjin Jung, Young Jun Kim, Jiyoun Hong
  Food Supplements and Biomaterials for Health.2023;[Epub]     CrossRef
• Low‑dose ionizing radiation attenuates high glucose‑induced hepatic apoptosis and immune factor release via modulation of a miR‑155‑SOCS1 axis
  Hongqiong Fan, Shanshan Liu, Benzheng Jiao, Xinyue Liang
  Molecular Medicine Reports.2023;[Epub]     CrossRef
• CT-based measurement of visceral adipose tissue volume as a reliable tool for assessing metabolic risk factors in prediabetes across subtypes
  Jihyun Kim, Keunyoung Kim
  Scientific Reports.2023;[Epub]     CrossRef
• The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
  Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
  Diagnostics.2023; 13(21): 3316.     CrossRef
• Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
  Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
  Scientific Reports.2023;[Epub]     CrossRef
• Prevalence of High and Moderate Risk of Liver Fibrosis Among Patients With Diabetes at a Noncommunicable Diseases (NCD) Clinic in a Primary Healthcare Center in Northern India
  Anubhav Mondal, Aninda Debnath, Ghurumourthy Dhandapani, Abhishek Sharma, Shveta Lukhmana, Geeta Yadav
  Cureus.2023;[Epub]     CrossRef
• Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
  Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar
  International Journal of Diabetes in Developing Countries.2022; 42(2): 290.     CrossRef
• Lead, mercury, and cadmium exposures are associated with obesity but not with diabetes mellitus: Korean National Environmental Health Survey (KoNEHS) 2015–2017
  Min Kyong Moon, Inae Lee, Aram Lee, Hyunwoong Park, Min Joo Kim, Sunmi Kim, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Gi Jeong Cheon, Kyungho Choi, Young Joo Park, Jeongim Park
  Environmental Research.2022; 204: 111888.     CrossRef
• Association of Prenatal Famine Exposure With Inflammatory Markers and Its Impact on Adulthood Liver Function Across Consecutive Generations
  Shiwei Yan, Jingqi Ruan, Yu Wang, Jiaxu Xu, Changhao Sun, Yucun Niu
  Frontiers in Nutrition.2022;[Epub]     CrossRef
• Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry
  Cheng Hu, Xiaoyu Zhuang, Jiaqi Zhang, Tao Wang, Shengnan Du, Jinping Wang, Xuelian Peng, Qin Cao, Mingcai Zhang, Yuanye Jiang
  Laboratory Medicine.2022; 53(4): 360.     CrossRef
• Genistein—Opportunities Related to an Interesting Molecule of Natural Origin
  Ewa Garbiec, Judyta Cielecka-Piontek, Magdalena Kowalówka, Magdalena Hołubiec, Przemysław Zalewski
  Molecules.2022; 27(3): 815.     CrossRef
• Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
  Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Diabetes & Metabolism Journal.2022; 46(1): 104.     CrossRef
• Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study
  Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon
  Diabetes Research and Clinical Practice.2022; 184: 109208.     CrossRef
• Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany
  Yvonne Huber, Andreas Schulz, Irene Schmidtmann, Manfred Beutel, Norbert Pfeiffer, Thomas Münzel, Peter R. Galle, Philipp S. Wild, Karl J. Lackner, Jörn M. Schattenberg
  Hepatology Communications.2022; 6(6): 1457.     CrossRef
• Non-alcoholic fatty liver disease
  Rehab F. Abdel-Rahman
  Asian Pacific Journal of Tropical Biomedicine.2022; 12(3): 99.     CrossRef
• State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
  Yongin Cho, Yong-ho Lee
  Endocrinology and Metabolism.2022; 37(1): 38.     CrossRef
• Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
  Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
  Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
• The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
  Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Sociodemographic and genetic determinants of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients
  Muhammad Adnan, Abdul Wajid, Wasif Noor, Andleeb Batool, Muhammad Aasim, Kamran Abbas, Quratul Ain
  Journal of Genetic Engineering and Biotechnology.2022; 20(1): 68.     CrossRef
• Concordance between indirect fibrosis and steatosis indices and their predictors in subjects with overweight/obesity
  Gaggini Melania, Vigna Luisella, Di Piazza Salvina, Gori Francesca, Tirelli Amedea Silvia, Bamonti Fabrizia, Maltinti Maristella, Napolitano Filomena, Chatzianagnostou Kyriazoula, Cristina Vassalle
  Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.2022; 27(7): 2617.     CrossRef
• Stéatopathie métabolique hépatique évaluée par le FibroScan® avec contrôle des paramètres d’atténuation (CAP) chez la personne diabétique de type 2 en Côte d’Ivoire
  Jacko Abodo, Dimitri Kouamé, Jocelyne Danho, Moumouni Léilatou, Pierre Koffi-Dago, Adelaïde Hué, Assita Yao, Franck Kouassi, Anselme N’Guessan, Fulgence Bathaix
  Médecine des Maladies Métaboliques.2022; 16(6): 550.     CrossRef
• Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
  Stergios Kechagias, Mattias Ekstedt, Christian Simonsson, Patrik Nasr
  Hormones.2022; 21(3): 349.     CrossRef
• Association between organochlorine pesticides and nonalcoholic fatty liver disease in the National Health and Nutrition Examination Survey 2003–2004
  Hyunji Sang, Kyu-Na Lee, Chang Hee Jung, Kyungdo Han, Eun Hee Koh
  Scientific Reports.2022;[Epub]     CrossRef
• Increased Risk of NAFLD in Adults with Glomerular Hyperfiltration: An 8-Year Cohort Study Based on 147,162 Koreans
  Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Eun-Jung Rhee, Cheol-Young Park, Won-Young Lee, Ki Won Oh, Se Eun Park
  Journal of Personalized Medicine.2022; 12(7): 1142.     CrossRef
• Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim
  Diabetes & Metabolism Journal.2022; 46(4): 630.     CrossRef
• New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis
  Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
  Life.2022; 12(8): 1189.     CrossRef
• Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
  Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
  Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
  Biomedicines.2022; 10(10): 2375.     CrossRef
• Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
  Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
  Nutrients.2022; 14(23): 4994.     CrossRef
• The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study
  Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, Sang-Man Jin, Jae Hyeon Kim
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Association of Nonalcoholic Fatty Liver Disease with Coronary Artery Disease in Type 2 Diabetes Mellitus
  Neelakandan Ramya, Golepu Karthikeya, Sethu Prabhu Shankar
  Acta Medica International.2022; 9(1): 31.     CrossRef
• NAFLDin type 2 diabetes mellitus: Still many challenging questions
  Simona Cernea, Itamar Raz
  Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
• The protective effect of shrimp cooked in different methods on high-cholesterol- induced fatty liver in rats
  Nora A. AlFaris, Ghedeir M. Alshammari, Jozaa Z. AlTamimi, Lujain A. AlMousa, Nora M. AlKehayez, Dalal H. Aljabryn, Reham I. Alagal, Mohammed A. Yahya
  Saudi Journal of Biological Sciences.2021; 28(1): 170.     CrossRef
• Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years
  Hye Won Lee, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
  Journal of Diabetes and its Complications.2021; 35(1): 107747.     CrossRef
• Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study
  Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Takashi Miki, Hironobu Toda, Kentaro Ejiri, Masatoki Yoshida, Yusuke Nanba, Masashi Yoshida, Kazufumi Nakamura, Hiroshi Morita, Hiroshi Ito
  Cardiovascular Diabetology.2021;[Epub]     CrossRef
• Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study
  Chileka Chiyanika, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Henry Lik-Yuen Chan, Steve C. N. Hui, David K. W. Yeung, Winnie C. W. Chu
  Clinical and Translational Gastroenterology.2021; 12(2): e00300.     CrossRef
• Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
  Sook Jung Lee, Byung-Wan Lee
  The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
• Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
  Jingxuan Lian, Jianfang Fu
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
  In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
  Scientific Reports.2021;[Epub]     CrossRef
• Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
  Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada
  Journal of Clinical Medicine.2021; 10(9): 2040.     CrossRef
• Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy
  Jin Yoo, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
  Metabolism.2021; 120: 154798.     CrossRef
• Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
  Jing Du, Sanbao Chai, Xin Zhao, Jianbin Sun, Xiaomei Zhang, Lili Huo
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 2399.     CrossRef
• Association between toothbrushing and non-alcoholic fatty liver disease
  Ji-Youn Kim, Yong-Moon Park, Gyu-Na Lee, Hyun Chul Song, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko, Houkai Li
  PLOS ONE.2021; 16(5): e0243686.     CrossRef
• Non‐alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey
  Joon Ho Moon, Bo Kyung Koo, Won Kim
  Journal of Cachexia, Sarcopenia and Muscle.2021; 12(4): 964.     CrossRef
• Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Won Euh, Soo Lim, Jin-Wook Kim
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice
  Fatemeh Kazeminasab, Sayed Mohammad Marandi, Maryam Baharlooie, Mohammad Hossein Nasr-Esfahani, Kamran Ghaedi
  Nutrition & Metabolism.2021;[Epub]     CrossRef
• Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
  Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
  Journal of the Endocrine Society.2021;[Epub]     CrossRef
• Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
  Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
  Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
• The association of hepatic steatosis and fibrosis with heart failure and mortality
  Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
  Cardiovascular Diabetology.2021;[Epub]     CrossRef
• Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease
  Seung Joon Choi, Seong Min Kim, Yun Soo Kim, Oh Sang Kwon, Seung Kak Shin, Kyoung Kon Kim, Kiyoung Lee, Ie Byung Park, Cheol Soo Choi, Dong Hae Chung, Jaehun Jung, MunYoung Paek, Dae Ho Lee
  Diabetes & Metabolism Journal.2021; 45(5): 739.     CrossRef
• Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
  Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
• The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases
  Hüseyin Vural, Ferah Armutcu, Omer Akyol, Ralf Weiskirchen
  Clinica Chimica Acta.2021; 523: 374.     CrossRef
• Increased Visit-to-Visit Liver Enzyme Variability Is Associated with Incident Diabetes: A Community-Based 12-Year Prospective Cohort Study
  Kyuhoon Bang, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
  Diabetes & Metabolism Journal.2021; 45(6): 890.     CrossRef
• Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
  Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects
  Hwi Seung Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Chang Hee Jung, Joong-Yeol Park, Hong-Kyu Kim, Woo Je Lee
  Journal of Clinical Medicine.2021; 11(1): 41.     CrossRef
• The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study
  Jung-Min Lee, Yong-Moon Park, Jae-Seung Yun, Yu-Bae Ahn, Kang-Moon Lee, Dae Bum Kim, Ji Min Lee, Kyungdo Han, Seung-Hyun Ko, Ming-Lung Yu
  PLOS ONE.2020; 15(1): e0226351.     CrossRef
• Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study
  Hyeok-Hee Lee, Yongin Cho, Young Ju Choi, Byung Wook Huh, Byung-Wan Lee, Eun Seok Kang, Seok Won Park, Bong-Soo Cha, Eun Jig Lee, Yong-ho Lee, Kap Bum Huh
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
  Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
  Endocrinology and Metabolism.2020; 35(1): 165.     CrossRef
• Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
  Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors
  Muharrem Bayrak
  The Aging Male.2020; 23(5): 1275.     CrossRef
• Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes
  Yali Zhang, Rong Shi, Liang Yu, Liping Ji, Min Li, Fan Hu
  Diabetes Therapy.2020; 11(9): 2057.     CrossRef
• Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
  Dae Ho Lee
  Endocrinology and Metabolism.2020; 35(2): 243.     CrossRef
• Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
  Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
  Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
• Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes
  D.H. Seo, Y.-h. Lee, S.W. Park, Y.J. Choi, B.W. Huh, E. Lee, K.B. Huh, S.H. Kim, B.-S. Cha
  Diabetes & Metabolism.2020; 46(5): 362.     CrossRef
• Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin
  Luana A. Biondo, Alexandre A. S. Teixeira, Karen C. de O. S. Ferreira, Jose C. R. Neto
  Current Pharmaceutical Design.2020; 26(9): 932.     CrossRef
• Diabetes and Metabolism Journal in 2020: Good to Great
  In-Kyung Jeong
  Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
• Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
  Soung Won Jeong
  Clinical and Molecular Hepatology.2020; 26(2): 185.     CrossRef
• The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study
  Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
  Journal of Trace Elements in Medicine and Biology.2020; 62: 126601.     CrossRef
• Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
  Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
  Medicine.2020; 99(33): e21038.     CrossRef
• Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
  Zhipeng Liu, Yang Zhang, Sarah Graham, Xiaokun Wang, Defeng Cai, Menghao Huang, Roger Pique-Regi, Xiaocheng Charlie Dong, Y. Eugene Chen, Cristen Willer, Wanqing Liu
  Journal of Hepatology.2020; 73(2): 263.     CrossRef
• Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
  Marieke de Vries, Jan Westerink, Karin H A H Kaasjager, Harold W de Valk
  The Journal of Clinical Endocrinology & Metabolism.2020; 105(12): 3842.     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
• Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
  Eun-Jung Rhee
  Endocrinology and Metabolism.2019; 34(3): 226.     CrossRef
• Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
  Anastasia Kontana, Konstantinos Tziomalos
  World Journal of Gastroenterology.2019; 25(28): 3664.     CrossRef

Citations

Citations to this article as recorded by  

• Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  Jing Wang, Xin Li, Yang Li, Chen Lei
  BMC Endocrine Disorders.2024;[Epub]     CrossRef
• Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
  Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi
  Expert Opinion on Pharmacotherapy.2024; 25(7): 925.     CrossRef
• Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes
  Derun Taner Ertugrul, Erdal Kan, Cigdem Bahadir Tura, Haci Bayram Tugtekin, Hayati Ayakta, Mehmet Celebioglu, Ceren Yılmaz, Onur Utebay, Ilhan Yetkin, Eren Gurkan, Kerem Sezer, Ramazan Gen, Suleyman Ozcaylak, Yildiz Okuturlar, Mehmet Coskun, Nilgun Govec
  International Journal of Diabetes in Developing Countries.2022; 42(1): 147.     CrossRef

• SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

  
  André J Scheen
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2765.     CrossRef
• Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
  Eugene Han, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
  Journal of Clinical Medicine.2020; 9(1): 259.     CrossRef
• Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials
  Atsunori Kashiwagi, Marina V. Shestakova, Yuichiro Ito, Masahiro Noguchi, Wim Wilpshaar, Satoshi Yoshida, John P. H. Wilding
  Diabetes Therapy.2019; 10(6): 2201.     CrossRef
• Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes
  Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(2): 1679.     CrossRef
• Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation
  Hongmei Wang, Gaoqiong Yao, Xi Chen, Jing Ouyang, Jiadan Yang
  Diabetes Research and Clinical Practice.2019; 157: 107867.     CrossRef
• Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
  Eugene Han, Ari Kim, Sung Jae Lee, Je-Yon Kim, Jae Hyeon Kim, Woo Je Lee, Byung-Wan Lee
  Diabetes Therapy.2018; 9(4): 1689.     CrossRef
• A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
  Marina V. Shestakova, John P.H. Wilding, Wim Wilpshaar, Reiner Tretter, Valeria L. Orlova, Andrey F. Verbovoy
  Diabetes Research and Clinical Practice.2018; 146: 240.     CrossRef
• Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
  Kyung‐Ah Han, Suk Chon, Choon Hee Chung, Soo Lim, Kwan‐Woo Lee, SeiHyun Baik, Chang Hee Jung, Dong‐Sun Kim, Kyong Soo Park, Kun‐Ho Yoon, In‐Kyu Lee, Bong‐Soo Cha, Taishi Sakatani, Sumi Park, Moon‐Kyu Lee
  Diabetes, Obesity and Metabolism.2018; 20(10): 2408.     CrossRef
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
• Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
• Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
  Min Kyong Moon, Kyu Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 974.     CrossRef
• Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
  Min Kyong Moon, Kyu-Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
  Diabetes & Metabolism Journal.2017; 41(5): 357.     CrossRef